Fabrice Chouraqui

Cellarity Inc. engages in the operation of platform to design medicines targeting the full cellular and molecular complexity of disease. The company was founded by Avak Kahvejian, James J. Collins, Noubar Afeyan, and Nicholas Plugis in 2017 and is headquartered in Cambridge, MA.

Flagship Pioneering (Flagship Pioneering) is a venture capital firm founded in 1982 by Ed M Kania and Noubar B Afeyan. The firm is headquartered in Cambridge, Massachusetts.

Orano Med SAS is a French biotechnology company that utilizes nuclear technology to develop new therapies for cancer patients with resistant forms of cancer. The company is based in Châtillon, France, and the CEO of the company is Julien Dodet. The company specializes in targeted alpha therapy treatments, which combines biological molecules to target cancer cells with the properties of lead-212 (212pb) to destroy them while limiting the impact on surrounding healthy cells. Orano Med has formed collaborations with prestigious institutions and biopharmaceutical companies to develop several treatments using 212pb combined with various targeting agents. The company has 212pb manufacturing facilities, laboratories, and R&D centers in France and the United States and is currently investing to expand its GMP-manufacturing capacities for 212pb radiolabeled pharmaceuticals. Orano Med is ultimately controlled by the Government of France.

Novartis Pharmaceuticals Corp. develops, manufactures, and markets prescription drugs. It manufactures and markets prescription drugs used to treat a number of diseases and conditions including cardiovascular, dermatological, central nervous system, bone disease, cancer, organ transplantation, psychiatry, infectious disease, and respiratory. The company was founded in 1996 and is headquartered in East Hanover, NJ.